-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Downgrades Apellis Pharmaceuticals to Equal-Weight, Raises Price Target to $41

Benzinga·04/17/2026 13:08:15
Listen to the news
Wells Fargo analyst Derek Archila downgrades Apellis Pharmaceuticals (NASDAQ:APLS) from Overweight to Equal-Weight and raises the price target from $26 to $41.